Tesamorelin is a compounded GHRH analogue that stimulates your pituitary gland to produce growth hormone naturally — not synthetic HGH. Clinically studied for visceral fat reduction. Prescribed. Compounded by a licensed 503B pharmacy. Delivered monthly.
Tesamorelin was originally FDA-approved for HIV-associated lipodystrophy. It is prescribed off-label by licensed providers for body composition. Individual results vary and are not guaranteed.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the signal your hypothalamus naturally sends to the pituitary gland to trigger growth hormone release. Rather than introducing exogenous, synthetic HGH from outside the body, tesamorelin works with your body's existing machinery. It tells the pituitary to produce and release its own growth hormone, in a physiologically appropriate pulsatile pattern.
This distinction is clinically significant. Synthetic HGH bypasses the body's natural feedback regulation, which is why it carries a more pronounced side-effect profile and requires careful monitoring. Tesamorelin preserves that feedback loop — your pituitary responds to physiological signals and self-regulates as it would naturally.
The primary clinically studied outcome is visceral adipose tissue (VAT) reduction — the deep abdominal fat that accumulates around organs and is associated with elevated metabolic and cardiovascular risk. Tesamorelin was originally FDA-approved for HIV-related lipodystrophy and is now prescribed off-label by licensed providers for broader body composition and metabolic optimization. Compounded by a licensed 503B outsourcing facility. Provider-prescribed after evaluation.
Not synthetic HGH.
A signal that makes your body
produce its own.
Targets visceral fat — the metabolically active adipose tissue that diet and exercise alone often fail to move.
Prescribed by a licensed physician.
Compounded by a 503B pharmacy.
Delivered monthly. If approved.
Your provider will evaluate candidacy based on your intake, health history, and goals. Here is how tesamorelin works and what differentiates it from other body composition tools.
Important distinction: Tesamorelin is not synthetic HGH. It stimulates your pituitary gland to produce growth hormone naturally — preserving your body's own feedback regulation. This is meaningfully different in mechanism, safety profile, and regulatory classification from exogenous growth hormone administration.
Off-label use. Prescription subject to provider approval. Results vary. Not a guarantee of outcomes. Compounded medications are not FDA-approved as finished drug products.
Tesamorelin's primary clinically studied outcome is reduction of visceral adipose tissue — the deep abdominal fat that accumulates around organs. This is distinct from subcutaneous fat (the fat you can pinch). VAT is metabolically active, associated with elevated cardiovascular and metabolic risk, and notoriously resistant to diet and exercise alone. Provider-guided protocols, results vary.
Rather than introducing HGH directly, tesamorelin signals the pituitary gland to produce and release its own growth hormone — maintaining the body's natural feedback regulation. This pulsatile, physiologically appropriate GH release is what differentiates tesamorelin from synthetic HGH and underlies its more favorable tolerability profile when appropriately prescribed.
Tesamorelin elevates IGF-1 (insulin-like growth factor 1), the downstream mediator of GH's anabolic effects. Increased IGF-1 supports lean muscle maintenance, tissue repair, and recovery — particularly relevant for active individuals running concurrent training protocols. Your provider monitors IGF-1 levels to guide dosing appropriately.
Improving the ratio of visceral adipose tissue to lean mass has documented downstream effects on metabolic markers — including improvements in triglycerides, waist circumference, and body composition indices. Tesamorelin addresses these outcomes at a mechanistic level rather than through caloric deficit alone. Effective as a standalone protocol or stacked with GLP-1 for comprehensive metabolic intervention.
You've addressed diet. Your training is consistent. Visceral fat remains the stubborn variable — particularly in the abdominal region. Tesamorelin targets that specific adipose depot at a hormonal level, where lifestyle interventions have diminishing returns. Provider evaluation required before prescribing.
GLP-1 protocols drive weight loss. Tesamorelin refines the composition of that loss — specifically targeting deep abdominal fat while supporting muscle maintenance through IGF-1 elevation. Many patients run both protocols concurrently for comprehensive body recomposition outcomes. Provider-guided, results vary.
You treat body composition as a longevity variable. Visceral adiposity is an independent predictor of metabolic and cardiovascular risk. Tesamorelin addresses that variable with clinical precision — not a consumer wellness product, but a physician-prescribed, pharmacologically targeted intervention. If approved after evaluation.
Your intake screens for all relevant contraindications. Every candidate is reviewed by a licensed physician before any prescription is issued. Diabetic patients who are candidates will receive provider guidance on glucose monitoring during the protocol. If you're borderline on any criteria, your provider will advise you directly.
A structured medical questionnaire covering health history, current medications, goals, and contraindication screening — including cancer history, pituitary function, and diabetes status. Under five minutes. No video call. Completed on your schedule.
A board-certified physician reviews your intake within 48 hours. They evaluate candidacy, assess contraindications, review relevant history, and issue your prescription if approved. If not approved, you're notified immediately with clinical reasoning — no charge.
Your tesamorelin ships from a licensed 503B compounding pharmacy — temperature-controlled packaging, tracked delivery, direct to your door. Injection supplies included. No pharmacy visit. No insurance required. Provider-prescribed formulation only.
Monthly provider check-ins, IGF-1 monitoring, dosing adjustments based on your response, and direct messaging access to your care team. If you are diabetic, glucose monitoring guidance is built into your protocol. Active clinical management throughout — not set and forget.
GLP-1 got me to 185. Tesamorelin got me to the version of 185 that I actually wanted. The difference is in the mirror — and in the DEXA scan. Visceral fat down significantly. Muscle maintained. That's the outcome I was looking for.
I prescribed tesamorelin before I ever took it. When I started my own protocol, the visceral fat response was exactly what the literature predicted. It works — and it works through a mechanism that's meaningfully different from synthetic HGH. That distinction matters clinically.
I did six months on GLP-1 first. Added tesamorelin for the second six. The combination is what actually moved my body composition in a meaningful way. The abdominal fat that hadn't responded to anything else — that's where the change showed up.
Individual results vary and are not typical. Testimonials reflect patient-reported outcomes and are used as illustrations only. Results are not guaranteed. All patients are under licensed physician supervision. Tesamorelin is prescribed off-label for body composition; it was originally FDA-approved for HIV-associated lipodystrophy.
GLP-1s are the most clinically validated fat loss tools available. But they work systemically — total body weight. When the scale stops moving but your midsection hasn't caught up, that's a different problem. Visceral fat doesn't respond to appetite suppression. It responds to growth hormone stimulation.
Tesamorelin targets what GLP-1 can't reach. That's not a flaw in either treatment — it's why they work together.
Start Assessment →Subscriptions renew monthly. Cancel anytime before your renewal date — no fees, no calls required. Provider review is required before any prescription is issued. All treatments require physician approval. Tesamorelin is prescribed off-label for body composition. Results vary. Compounded medications are not FDA-approved as finished drug products. FSA/HSA eligibility depends on your individual plan.
This is the most important distinction to understand. Tesamorelin is not HGH — it is a GHRH analogue, a signal that tells your pituitary to produce its own growth hormone. Synthetic HGH bypasses this system entirely: it introduces exogenous growth hormone from outside the body, overriding your pituitary's natural feedback regulation. Tesamorelin works upstream, stimulating your pituitary through the same pathway your hypothalamus would use naturally. This preserves the body's self-regulating feedback loop, which is why tesamorelin's safety profile and regulatory classification differ meaningfully from exogenous HGH. If approved by your provider, the distinction matters for both mechanism and clinical management.
Visceral fat is the adipose tissue that sits deep in the abdominal cavity, surrounding your organs — liver, pancreas, intestines. It's distinct from subcutaneous fat (the layer just beneath the skin that you can physically grasp). Visceral fat is metabolically active in ways that subcutaneous fat is not: it secretes pro-inflammatory cytokines, correlates strongly with insulin resistance, and is an independent predictor of cardiovascular and metabolic risk. It is also notoriously resistant to standard caloric restriction and aerobic exercise protocols. Tesamorelin's primary clinically studied outcome — documented in the peer-reviewed literature on HIV-associated lipodystrophy — is reduction of this specific fat depot. Results vary; your provider will evaluate your candidacy and baseline before prescribing.
Yes — and this is one of the most clinically rational combinations in AnthologyRX's protocol library. GLP-1 agonists (semaglutide, tirzepatide) drive total body weight reduction through appetite suppression and metabolic signaling. Tesamorelin targets the specific composition of that weight change — preserving lean mass through IGF-1 elevation and concentrating fat loss on visceral adipose tissue. Many patients run both concurrently: GLP-1 for the overall reduction, tesamorelin for body composition precision. Your physician reviews all active medications during intake and advises on compatibility. Stacking is evaluated case-by-case based on your clinical picture, not upsell volume.
Published tesamorelin research — primarily conducted in populations with HIV-associated lipodystrophy — typically documents measurable visceral fat reduction over 26–52 weeks of continuous use. Most patients pursuing body composition outcomes should approach tesamorelin as a multi-month protocol rather than a short-cycle intervention. Individual results vary significantly based on baseline visceral adiposity, hormonal status, diet, training, and compliance. Your provider will evaluate your baseline during intake and provide realistic expectations. Subjective changes — improved recovery, body composition shifts visible in mirror and measurements — are commonly reported by 8–12 weeks in, but objective DEXA-confirmed VAT reduction is typically assessed at 3–6 months. Results are not guaranteed.
Yes — this is a real and important consideration. Growth hormone has counter-regulatory effects on insulin, meaning GH elevation can cause transient increases in blood glucose. In patients with normal glucose metabolism, these effects are typically modest and well-tolerated. In diabetic patients or those with pre-diabetes, tesamorelin requires closer monitoring and specific provider guidance. Your intake screens for diabetes status. Diabetic patients who are otherwise good candidates will receive a protocol that includes glucose monitoring guidance and more frequent provider check-ins. If you have poorly controlled diabetes, your provider may determine that tesamorelin is not appropriate at this time. This is not a contraindication to asking — it is a reason to have your provider evaluate your specific clinical situation thoroughly.
AnthologyRX automatically issues an itemized receipt with each delivery suitable for FSA/HSA reimbursement requests. Eligibility for prescription medications under FSA/HSA plans is generally strong, but it depends on your specific plan administrator's policies and whether your plan requires a Letter of Medical Necessity (LMN). Many patients successfully use FSA/HSA funds for compounded prescription protocols. Your care team can provide supporting documentation if your plan requires it. Check with your plan administrator for plan-specific eligibility — we cannot guarantee reimbursement but can provide all documentation on our end.
Your intake takes five minutes. Provider review within 48 hours. No waiting room. No contracts. No guesswork. If approved, your protocol ships within days.
